# ClinicalTrials.gov record NCT05302596

> PeptideScanner retained ClinicalTrials.gov record NCT05302596 at 2026-07-30T18:29:04.234Z. Its registry update date was 2025-04-17, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05302596-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-04-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05302596-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05302596-semaglutide-v1.json
- Content SHA-256: `872d72c745637cedd33b688891ee847865721764811c2b3d009da263c6e580cb`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT05302596 ([`ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9`](#source-ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05302596 at 2026-07-30T18:29:04.234Z. Its registry update date was 2025-04-17, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9`](#source-ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05302596 at 2026-07-30T18:29:04.234Z. Its registry update date was 2025-04-17, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9`](#source-ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9`](#source-ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9))

## Sources

<a id="source-ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9"></a>
- **ClinicalTrials.gov record NCT05302596 · retained source version 2025-04-17:bc6c3380b7c94f733f833433447c96a73cb7ffc862c99491a1ef6c86b35e8a71** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05302596) (`ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05302596." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05302596-semaglutide-v1.json SHA-256: 872d72c745637cedd33b688891ee847865721764811c2b3d009da263c6e580cb.